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Asthma is a complex disease comprising various phenotypes and endotypes, all
of which still need solid biomarkers for accurate classification. In a previous study,
we defined specific genes related to asthma and respiratory allergy by studying the
expression of 94 genes in a population composed of 4 groups of subjects: healthy
control, nonallergic asthmatic, asthmatic allergic, and nonasthmatic allergic patients. An
analysis of differential gene expression between controls and patients revealed a set
of statistically relevant genes mainly associated with disease severity, i.e., CHI3L1, IL-8,
IL-10,MSR1, PHLDA1, PI3, andSERPINB2. Here, we analyzedwhether these genes and
their proteins could be potential asthma biomarkers to distinguish between nonallergic
asthmatic and asthmatic allergic subjects. Protein quantification was determined by
ELISA (in serum) or Western blot (in protein extracted from peripheral blood mononuclear
cells or PBMCs). Statistical analyses were performed by unpaired t-test using the
Graph-Pad program. The sensitivity and specificity of the gene and protein expression
of several candidate biomarkers in differentiating the two groups (and the severity
subgroups) was performed by receiver operating characteristic (ROC) curve analysis
using the R program. The ROC curve analysis determined single genes with good
sensitivity and specificity for discriminating some of the phenotypes. However, interesting
combinations of two or three protein biomarkers were found to distinguish the asthma
disease and disease severity between the different phenotypes of this pathology
using reproducible techniques in easy-to-obtain samples. Gene and protein panels
formed by single biomarkers and biomarker combinations have been defined in easily
obtainable samples and by standardized techniques. These panels could be useful for
characterizing phenotypes of asthma, specifically when differentiating asthma severity.
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INTRODUCTION
The heterogeneity of the clinical phenotypes in asthma and
respiratory allergy shows the complexity of this type of
diseases, and this reflects the involvement of genetic and
environmental factors, and therefore, its multifactorial character.
Many investigations have aimed to identify the environmental
risk factors and genes associated with these diseases (1). Faced
with such great complexity, new techniques such as massive
analysis or omics have become important tools in efforts to
advance existing knowledge of the diagnosis, follow-up, and
treatment-monitoring of asthmatic, and allergic diseases, and
also in the search for risk-related or protective biomarkers and
the development of new drugs (2).
Precision medicine, an increasingly important approach to
the treatment and prevention of disease, has been defined by
the U.S. National Library of Medicine as a strategy that takes
into account the variability in genes, in the environment, and in
individual lifestyles. The end goal of precision medicine is to find
predictive parameters with which to select the most appropriate
prophylactic or therapeutic strategy for a given disease within a
specific group of patients (3). Precision medicine implicates that
individuals are classified as subpopulations that differ in their
susceptibility to a certain disease. To identify subpopulations of
patients or phenotypes (4), the approach of precision medicine is
based in the underlying mechanisms of the distinct forms of each
disease, that is, endotypes (5), using related measures that act as
biomarkers (6).
From a clinical point of view, asthma is a heterogeneous
disease usually characterized by chronic airway inflammation
with a great number of different phenotypes. Despite its clinical
complexity, most efforts to find new treatments for asthma
have centered on allergic asthma or asthma mediated by type
2 inflammation, which is responsible for disease in 50–80% of
asthmatic patients. These patients would be classified in the so
called type T2 or T2-high endotype. Type 2 immune response
has been extensively characterized and defined as an increase
of T-helper 2 (Th2) cytokines, mainly of IL4, IL5, and/or IL13
likely derived from both adaptive (mainly Th2 lymphocytes), and
innate, mainly innate lymphoid cells type 2 (ILC2) immune cells
resulting in eosinophilic airway infiltration. These patients are
allergic subjects with high total IgE levels and high eosinophil
counts. In comparison, 10–33% of subjects with asthma have
no associated allergy (nonallergic asthma), with a non-type
2 inflammation (non-T2 or T2-low endotype) (7), and the
mechanisms that contribute to the immune response are less
clear in these subjects. In many cases, instead of an eosinophilic
inflammation, there exists a prevalence of neutrophils (8–12). To
date, no directed therapy has been found to be effective against
this endotype (13).
The type-T2 biomarkers used in clinical practice are limited
to eosinophil counts in sputum and blood, FeNO (fractional
concentration of exhaled nitric oxide), and IgE levels in
serum. In addition to these markers, however, periostin is
becoming increasingly relevant in clinical practice, this despite
the findings of Korevaar et al., who showed that in severe
asthma, there is a poor correlation between the number of
eosinophils in blood, FeNO, periostin, and serum IgE levels on
the one hand and the number of eosinophils in sputum (14).
Therefore, conventional biomarkers of T2-high asthma show
limited sensitivity and specificity, and potential biomarkers are
still not available for routine use in clinical practice due to a
lack of validation and standardization. The T2-low endotype has
been less exhaustively characterized. It is associated with airway
neutrophilia and steroid insensitivity to airway obstruction
(15, 16). Some proposed biomarkers for this endotype include
neutrophilia in blood and sputum (17), serum IL-6, IL-8 in
sputum, and neutrophil elastase protein (18), though all have
numerous limitations. These novel biomarkers are targeted to
neutrophilic inflammation that can be originated by other causes
apart from asthma disease, for instance by high dosage of
corticosteroid medication (19), exposure to pollution, cigarette
smoke and bacterial infection. In a recent work, new gene and
protein biomarkers CHI3L1, IL-8, IL-10, MSR1, PHLDA1, PI3,
and SERPINB2, were proposed to discriminate healthy control
subjects from nonallergic asthmatic patients (T2-low) and to
measure asthma severity (20). The relevance of these potential
biomarkers in asthma and allergy diseases was extensively
discussed (21).
Thus, there remains an unmet clinical need in the study of
the mechanisms and biomarkers for both T2-high and T2-low
endotypes as concerns their ability to predict response to targeted
therapy (22). The development of solid biomarkers combined
with a deeper understanding of the pathology and physiology
of asthma will allow a more direct and effective treatment
of asthmatic patients through approaches based on precision
medicine (23). In this work, we seek to corroborate at genetic and
protein level the implication of previously described biomarkers
associated with allergic (T2-high) and nonallergic asthma (T2-
low or non T2) diseases in order to define their potential as
diagnostic and disease-severity biomarkers.
MATERIALS AND METHODS
Subjects
The study population comprised 60 unrelated subjects previously
described by Baos et al. (21): 30 patients with nonallergic asthma
(NA) and 30 patients with allergic asthma (AA). Different
biological samples (PBMCs and sera) were obtained from
the asthma biobank of the CIBERES (Ciber de Enfermedades
Respiratorias) located at the IIS-Fundación Jiménez Díaz-UAM in
Madrid (IIS-FJD-UAM) (24). Patients were diagnosed as having
severe, moderate, or mild asthma according to the Spanish
Guidelines for the Management of Asthma or GEMA (25).
Daily mean inhaled corticosteroids administration over the 6
months preceding diagnosis and during sample collection was
1,488 ± 541 µg in severe, 1,100 ± 977.75 µg in moderate,
and 450 ± 463.68 µg in mild asthmatic patients. On the
day of sample collection, the subjects did not take systemic
medication of any kind. Pulmonary function tests were carried
out and different parameters were determined, i.e., the predicted
percentage of forced vital capacity (% FVC), forced expiratory
volume in 1 s (% FEV1), and the post bronchodilator test (%
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PBD) or reversibility test. All subjects were tested by skin
prick test against a panel of common allergens, including mites
(Dermatophagoides pteronyssinus,Dermatophagoides farinae, and
Lepidoglyphus destructor), epithelia (cat and dog), cockroaches
(Blatella orientalis and Blatella germanica), pollens (Cypress,
banana shadow, olive, mixture of grasses, Artemisia, Parietaria,
and Salsola), and fungi (Alternaria, Cladosporium, Aspergillus,
and Penicillium). Written informed consent was obtained from
each subject in accordance with the Declaration of Helsinki.
Ethical approval for the study was obtained from the ethics and
research committees of the participating hospitals.
Peripheral Blood Mononuclear Cell
Isolation and Protein Extraction
Peripheral blood mononuclear cells (PBMCs) were isolated
from heparin-containing peripheral blood samples by gradient
centrifugation using Lymphoprep (Comercial Rafer, Zaragoza,
Spain) following the manufacturer’s instructions. PBMCs were
isolated in sterile conditions using endotoxin-free reagents. RNA
and total protein were isolated from PBMCs (106 cells) using
the Trizol method (Invitrogen, Carlsbad, CA, USA). RNA was
quantified and its purity was checked by spectrophotometry
using the nanodrop (ND-1000 Spectrophotometer) system.
Protein levels were quantified by applying the BCA method
(Thermo Fisher Scientific, Rockford, IL, USA).
Differential Gene Expression by qRT-PCR
Gene expression analyses were performed by qRT-PCR using
microfluidic cards following the protocols described by Baos
et al. (21).
Gene Selection
CPA3, CHI3L1, IL-1R2, IL-8, and PI3 were selected as candidate
biomarkers for both the NA and AA groups (significance
established at relative gene quantification of higher than 4 or
lower than 0.25 compared to the healthy control group) (24), as
these were the most relevant genes in the two asthma groups.
Genes that did not meet the strict criteria (RQ > 4 or <0.25)
in all of the comparisons (24) were not taken into account for
the protein expression analysis. In addition to this criterion, the
proteins CHI3L1, IL-8, IL-10, PI3, PHLDA1, and SERPINB2,
which were selected to compare the NA and AA groups, were
previously found to be the most relevant genes in the NA
group (21).
Soluble Protein Level Analysis of IL-8,
IL-10, CHI3L1, PI3, and POSTN
Using a commercially available ELISA kit, soluble biomarkers
were quantified in all the study subjects. Levels of CHI3L1, IL-
8, IL-10, PI3, and POSTN were measured in the subjects’ serum
using the human ELISA kits manufactured by R&D Systems
(Minneapolis, MN, USA) for CHI3L1, PI3, and POSTN; by
ImmunoTools (Friesoythe, Germany) for IL-10; and by Diaclone
(Besancon Cedex, France) for IL-8. The procedure was carried
out in accordance with each manufacturer’s protocol. POSTN, or
periostin, was analyzed at the protein level given its relevance as
a protein associated with allergic asthma (26, 27).
Protein Expression Analysis of PHLDA1
and SERPINB2
Protein determination of PHLDA1 and SERPINB2 was
performed by Western blot as these were not soluble proteins
or no commercial ELISA kit was available at the time. They
were quantified in the total protein extracted from PBMCs.
PHLDA1 was studied in 5 NA (3 severe and 2 moderate-mild)
and 6 AA subjects (3 severe and 3 moderate-mild), and we
studied SERPINB2 in 11 NA (6 with severe asthma and 5 with
moderate-mild diagnosis), and 11 AA subjects (6 with severe
asthma and 5 with moderate-mild diagnosis). We used the
Western blot procedure pertaining to the Invitrogen Western
Breeze R© Chemiluminescent Western Blot Immunodetection
Kit (Life Technologies, Carlsbad, CA, USA) as previously
described (24). PHLDA1 was detected with a rabbit anti-human
polyclonal PHLDA1 antibody (Thermo Fisher Scientific) at
a 1:500 dilution and SERPINB2 with the rabbit anti-human
polyclonal SERPINB2 antibody by R&D Systems at a dilution
of 1:250. The result was visualized using a luminescent image
analyzer: the ImageQuant LAS 4000 (GE Healthcare Life Science,
Little Chalfont, Buckinghamshire, UK). Data from specific
protein results were relative to β-Actin (dilution 1:1000; Cell
Signaling Technology, Danvers, MA, USA) expression.
ROC Curve Analysis at the Gene and
Protein Level
Sensitivity vs. specificity on ROC curve plots and the area
under the curve (AUC) are effective measures of accuracy when
evaluating the diagnostic ability of tests to discriminate the true
state of subjects, finding optimal cut-off values. A ROC curve was
constructed for the candidate biomarkers common to the NA
and AA groups, examining severity and total expression at the
gene level. At the protein level, CHI3L1, IL-8, IL-10, SERPINB2,
PHLDA1, PI3, and POSTN were studied, as these were found to
be the most relevant in previous research (20, 21). Four kinds
of comparisons were performed: total NA group vs. total AA
group, severe NA patients vs. severe AA patients, moderate-
mild NA patients vs. moderate-mild AA patients, and severe AA
patients vs. moderate-mild AA patients. Comparison between
severe NA patients vs. moderate-mild NA patients has already
been described by Baos et al. (20). A guide for interpreting the
ROC curves has been previously described (20). Only the results
with a 95% confidence interval (95% CI) between 0.70 and 1 were
considered statistically significant.
Statistical Analysis
The levels and relative expression of the proteins studied were
compared between groups by unpaired t-test, using the Graph-
Pad InStat 3 program. Statistical significance was established
at a two-tailed P-value < 0.05. The ROC curve analyses were
performed using the R program.
RESULTS
Subjects
The study population has been described previously (21), and
Table 1 summarizes the demographic and clinical parameters
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of the two groups studied (Table 1A). The NA patients were
significantly older than the AA subjects (58.03 ± 13.14 vs. 42.37
± 15.44 years, respectively; P< 0.0001). There weremore women
than men in both groups and in a similar proportion. Smoking
habits were similar in both groups. The NA group presented
no allergic symptoms, with negative results on the skin prick
test against a panel of common allergens. In contrast, the AA
patients were all allergic to airborne allergens. Mean levels of
total IgE were significantly higher in the AA group (371.64 ±
437.69 IU/ml) compared to the NA patients (82.04 ± 80.63
IU/ml) (P < 0.001). The concomitant diseases found in the
NA group were as follows: nonatopic rhinitis (80%), sinusitis
(50%), polyposis (43.3%), esophageal reflux (20%), eczema
(6.67%), and rash (6.67%); and in the AA group, rhinitis (90%),
esophageal reflux (50%), sinusitis (26.67%), rash (16.67 %),
polyposis (10%), and eczema (3.33%). Each group contained 50%
severe asthma patients, and the other 50%moderate-mild asthma
subjects. The %FEV1 and %FVC values were similar. When
these parameters were analyzed according to disease severity
(Table 1B), significant differences were found only in the NA
group (%FEV1: 66.33 ± 16.62 severe patients vs. 85.38 ± 21.03
moderate-mild patients, P= 0.0127; %FVC: 69.93± 19.94 severe
patients vs. 94± 19.52 moderate-mild patients, respectively, P =
0.0031). The percentage and number of eosinophils in the NA
group were normal (3.83 ± 2.24 vs. 273.86 ± 137.13 cells/µl)
(cut-off: 1–4% and 50–450 cells/µl). No significant differences
were found in the presence of eosinophils between severe and
moderate-mild NA subjects (percentage: 3.73 ± 2.48 vs. 4.22
± 1.25%, respectively; number: 264 ± 152.96 vs. 310 ± 52.57
cells/µl, respectively). In contrast, eosinophil presence was high
among AA patients, with a percentage of 5.70 ± 3.40% and
a count of 625.60 ± 999.28 cells/µl. No significant differences
were observed when comparing the severe and moderate-mild
AA patients (percentage: 5.89 ± 3.70 vs. 5.28 ± 2.85%, number:
739.50 ± 1180.74 vs. 359.83 ± 220.55 cells/µl, severe AA vs.
moderate-mild AA, respectively) (Table 1B).
ROC Curve Analysis of Gene Expression
The five genes studied were classified into five categories (20),
as seen in Table 2. When comparing the two groups of patients,
CPA3 (AUC value: 0.77) was considered a good biomarker for
their differentiation. The rest (CHI3L1, IL-1R2, IL-8, and PI3)
were classified as regular. To discriminate patients with severe
disease in the two asthma groups, PI3 (AUC value: 0.78) was
seen to be a good biomarker. The gene expression of CPA3
and IL-8 (AUC value: 0.89 and 0.87, respectively) were effective
biomarkers for distinguishing moderate-mild NA subjects from
moderate-mild AA patients. When comparing the severe and
moderate-mild AA groups, neither of the genes were considered
good, as was observed in the severe NA vs. moderate-mild NA
comparison (20).
Protein Expression Analysis
Figures 1, 2 provide a summary of the relative quantification
(RQ) of the protein expression of PHLDA1 and SERPINB2
and mean sera levels (pg/ml) of CHI3L1, IL-8, IL-10, PI3, and
POSTN. The study of CHI3L1, PI3, and POSTN gave detectable TA
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TABLE 1B | Characteristics of the study population.
N Total IgE (IU/ml) % FVC % FVE1 % Eosinophils Eosinophils count (cells/µl)
(B) CHARACTERISTICS OF THE POPULATION ACCORDING TO ASTHMA SEVERITY
Severe NA
subjects
15 88.85 ± 61.57 69.93 ± 19.94 66.33 ± 16.62 3.73 ± 2.48 264.00 ± 152.96
Moderate/mild NA
subjects
15 75.24 ± 97.87 94.00 ± 19.52# 85.38 ± 21.03* 4.22 ± 1.25 310.00 ± 52.57
Severe AA
subjects
15 306.27 ± 204.53 71.93 ± 12.38 69.27 ± 13.36 5.89 ± 3.70 739.50 ± 1180.74
Moderate/mild AA
subjects
15 417.13 ± 583.84 79.13 ± 19.70 77.40 ± 18.31 5.28 ± 2.85 359.83 ± 220.55
NA, nonallergic asthmatic; AA, allergic asthmatic; % FVC, percentage of predicted value of forced vital capacity; % FEV1, percentage of predicted value of forced expiratory volume in 1
second. *Statistically significant comparison (p < 0.05) between the severe NA and moderate/mild NA group. #Statistically significant comparison (p < 0.005) between the severe NA
and moderate/mild NA group.
TABLE 2 | Classification of biomarkers by receiver operating characteristic (ROC)
curves analysis at the genetic level.
Comparison/
AUC value
Excellent
(AUC:
0.98–1)
Very Good
(AUC:
0.91–0.97)
Good
(AUC:
0.76–0.90)
Regular
(AUC: 0.61–0.75)
Poor
(AUC:
0.50–0.60)
Total NA
vs.
Total AA
CPA3: 0.77 CHI3L1: 0.61
IL-1R2: 0.74
IL-8: 0.72
PI3: 0.74
Severe NA
vs.
severe AA
PI3: 0.78 CPA3: 0.63
IL-1R2: 0.73
IL-8: 0.61
CHI3L1 < 0.50
Moderate-mild NA
vs.
moderate-mild AA
CPA3: 0.89
IL-8: 0.87
CHI3L1: 0.74
IL-1R2: 0.71
PI3: 0.73
Severe AA
vs.
moderate-mild AA
CHI3L1: 0.69
CPA3: 0.67
IL-1R2: 0.65
IL-8: 0.63
PI3: 0.50
Summary of the ROC curve analysis of the gene biomarkers common to both asthma
groups. AUC, area under the curve. ND, not determined due to a lack of data; NA,
nonallergic asthma; AA, allergic asthma.
protein levels in all of the assays performed. However, we found a
53.33 and 63.3% of undetected values of IL-8 and IL10 in samples
of NA patients and 56.67 and 30% in AA patients, respectively.
The protein level of POSTN was significantly higher in the
NA subjects (18,679.59 ± 8,086.07 pg/ml) when compared to
the AA subjects (15,199.93 ± 4,263.88 pg/ml) (P = 0.0415)
(Figure 1G). Though the results were not statistically significant,
the protein expression of PHLDA1 (NA patients: 0.062 ± 0.064
RQ; AA patients: 0.025 ± 0.027 RQ) (Figure 1A), SERPINB2
(NA patients: 0.11 ± 0.05 RQ; AA patients: 0.08 ± 0.04
RQ)(Figure 1B), and IL-8 (NA patients: 452.28 ± 357.72 pg/ml;
AA patients: 207.02 ± 328.90 pg/ml) (Figure 1D) were higher in
the NA group than in the AA group. CHI3L1 (Figure 1C) and IL-
10 (Figure 1E) showed higher levels in the AA group (CHI3L1,
AA vs. NA group: 22,812.55 ± 3,573.46 pg/ml vs. 19,364.77 ±
9,046.25 pg/ml, respectively; IL-10, AA vs. NA group: 194.96
± 171.81 pg/ml vs. 157.27 ± 170.82 pg/ml, respectively).
PI3 presented similar levels between the two asthma groups
(Figure 1F).
Furthermore, statistically significant differences were
observed in the protein expression of SERPINB2, CHI3L1, IL-8,
and POSTN when comparing severity subgroups (Figure 2).
The protein expression of SERPINB2 among severe NA patients
was higher than the protein expression of SERPINB2 in severe
AA patients (0.13 ± 0.07 and 0.06 ± 0.02 RQ, respectively,
P = 0.0367) (Figure 2B). As also observed in Figure 2B, the
moderate-mild AA group showed significantly higher SERPINB2
expression than the severe AA group (0.11± 0.04 vs. 0.06± 0.02
RQ, respectively, P = 0.0367). For CHI3L1 there were significant
differences between the severe NA group and the severe AA
group (P= 0.0021) (Figure 2C), with lower CHI3L1 levels in NA
patients. Significant differences were found when comparing the
levels of IL-8 in moderate-mild NA patients to moderate-mild
AA patients (P = 0.0433) (Figure 2D), with lower levels found
in AA patients. In Figure 2G, the protein levels of POSTN in
serum are shown according to the severity of asthma. The levels
of POSTN were higher in the severe NA patients when compared
to the severe AA patients (P = 0.0468).
Though PHLDA1, IL-10, and PI3 did not present significant
differences in protein levels between the severity subgroups
(Figure 2), IL-10 showed higher levels in severe asthma patients
(severe NA group: 200.60 ± 219.85 pg/ml and moderate-mild
NA group: 105.27 ± 79.62 pg/ml; severe AA group: 211.49 ±
193.94 pg/ml and moderate-mild AA group 168.11 ± 136.13
pg/ml) (Figure 2E). PHLDA1 had the highest levels in the two
NA severity subgroups, especially when patients had a moderate-
mild diagnosis [severe NA (n = 3): 0.05 ± 0.07 RQ, moderate-
mild NA (n= 2): 0.08± 0.10 RQ, severe AA (n= 3): 0.03± 0.04
RQ, moderate-mild AA (n = 3): 0.02 ± 0.01 RQ] (Figure 2A),
although this data needs to be confirmed in a bigger population.
PI3 had similar protein levels in all severity subgroups (severe
NA: 6225.03 ± 1999.11 pg/ml, moderate-mild NA: 5824.14 ±
2624.29 pg/ml, severe AA: 6390.10 ± 2226.27 pg/ml, moderate-
mild AA: 6784.24± 2311.30 pg/ml) (Figure 2F).
ROC Curve Analysis of Protein Expression
When comparing AUC values between the NA group and
the AA group (Table 3), interesting biomarkers were seen
in patients with severe asthma. The protein expression of
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FIGURE 1 | Mean levels of protein expression. (A) Mean levels of PHLDA1. (B) Mean levels of SERPINB2. (C) Mean levels of CHI3L1. (D) Mean levels of IL-8. (E)
Mean levels of IL-10. (F) Mean levels of PI3. (G) Mean levels of POSTN. *Statistically significant comparison (P < 0.05) between the indicated groups. Protein levels of
PHLDA1 and SERPINB2 were measured by Western blot in 5 NA and 6 AA subjects, and 11 NA and 11 AA, respectively. Densitometric analysis was done in
individual blots (see “Materials and Methods”) using the β-actin protein for normalization. CHI3L1, IL-8, IL-10, PI3, and POSTN were quantified by ELISA in all patients
included in the study population. The levels and relative expression of the proteins studied were compared among groups by unpaired t-test, using the Graph-Pad
InStat 3 program. The error bars indicate the standard deviation. NA, total nonallergic asthma group; AA, total allergic asthma group.
CHI3L1 and SERPINB2 were good candidates for discriminating
severe NA from severe AA subjects (AUC value: 0.82 and
0.78, respectively). SERPINB2 (AUC value: 0.77) was a good
candidate for distinguishing disease severity in the AA group.
IL-8 was also classified as good for differentiating severe AA
patients from moderate-mild AA patients (AUC value: 0.82)
and, as described by Baos et al. (20), also when discriminating
severe NA from moderate-mild NA (AUC value: 0.76). For all
other comparisons, the AUC values of the individual proteins
studied were insufficient for a good classification (Table 3).
Consequently, the ROC curve analysis was determined by
combining the protein expression of two (Table 3) and three
(Table 4) biomarkers. There was an improvement in sensitivity
and specificity when several biomarkers were combined in all
of the comparisons. It is worth highlighting the presence of
POSTN in many of the combinations. The combination of two or
three biomarkers gave combinations with AUC values over 0.75,
meaning that good, very good, or excellent test were found when
discriminating the two asthma groups and their severity.
To summarize, we ranked the best biomarkers or combination
of biomarkers by their ability to discriminate each condition
analyzed; all had a predictive accuracy that was at least good
(AUC > 0.75) and a 95% CI of between 0.70 and 1. These
rankings are shown in Table 5. Briefly, the combinations of IL-10
and POSTN, CHI3L1 with IL-10 and POSTN, or CHI3L1 with
IL-8 and POSTN are proposed as good or very good sets of
biomarkers to differentiate between the two types of asthma.
For severity discriminations, IL-10+ POSTN, PI3+ SERPINB2,
CHI3L1 + POSTN, and CHI3L1 + IL-8 + POSTN may be
very good candidates for differentiating severe asthma diagnosis
within the NA and AA groups; and CHI3L1 with IL-10 and
POSTNmay be useful for distinguishing between moderate-mild
asthma patients (NA vs. AA). Furthermore, the combination of
the protein expressions of POSTN and SERPINB2 was observed
as a very good discriminator for the severity of AA patients
(severe AA vs. moderate-mild AA). Added to this, and as found
previously (20), POSTN, and SERPINB2, PI3 combined with
POSTN and SERPINB2, or CHI3L1 with IL-8 and POSTN
were found to be good, very good, and excellent biomarkers,
respectively, as concerns their capacity to distinguish patients
with severe NA from moderate-mild NA.
DISCUSSION
While the currently used therapeutic approach for asthma is
effective in some patients, there remains an unmet need for
Frontiers in Immunology | www.frontiersin.org 6 May 2019 | Volume 10 | Article 1051
Baos et al. Allergic and Nonallergic Asthma Biomarkers
FIGURE 2 | Mean levels of protein expression by asthma severity subgroup. (A) Mean levels of PHLDA1. (B) Mean levels of SERPINB2. (C) Mean levels of CHI3L1.
(D) Mean levels of IL-8. (E) Mean levels of IL-10. (F) Mean levels of PI3. (G) Mean levels of POSTN. *Statistically significant comparison (p < 0.05) between the
indicated groups. **Statistically significant comparison (p < 0.005) between the indicated groups. Protein levels of PHLDA1 were measured by Western blot in 3
severe NA and 2 moderate-mild NA patients, 3 patients with severe AA, and 3 with moderate-mild AA. Protein levels of SERPINB2 were measured by Western blot in
6 severe NA and AA subjects and in 5 moderate-mild NA and AA patients. Densitometric analysis was done in individual blots (see “Materials and Methods”) using the
β-actin protein for normalization. CHI3L1, IL-8, IL-10, PI3, and POSTN were quantified by ELISA in all patients studied. The levels and relative expression of the
proteins studied were compared among groups by unpaired t-test, using the Graph-Pad InStat 3 program. The error bars indicate the standard deviation. S, group of
subjects with severe asthma; MM, group of subjects with moderate-mild asthma.
a wider ray of treatment options, especially in uncontrolled
severe asthma. Some studies propose specific approaches for
the management of severe, difficult-to-treat asthma based on
specific phenotype characteristics and biomarkers (28). The
allergic asthmamediated by type T2 inflammation (T2 endotype)
has been the center of attention in the search for biomarkers
and for the development of therapeutic drugs used for managing
eosinophilic inflammation. Comparatively, however, the asthma
with non-T2 mediated immune response (non-T2 endotype) has
received scant attention (29). Therefore, insufficient efforts have
been devoted to this type of asthma, and biologically targeted
therapies are an underdeveloped field.
The long-term aim is to establish an approach that modifies
the disease, and this could be achieved through the development
of drugs that target specific inflammatory pathways within
asthma pathogenesis (30). Nevertheless, it is important to
identify patients with a higher likelihood of responding to this
kind of therapies. If proven effective, predictive biomarkers
would mark a change in the classification and conventional
treatment of asthma, putting an end to the “one size fits all”
approach (31). Technologies of massive analysis, or omics, such
as transcriptomics, proteomics, lipidomics, and metabolomics,
are becoming very useful in the discovery of new biomarkers and
in discriminating phenotypes in blood, sputum, bronchoalveolar
lavage, or tissue samples derived from affected organs. Omics
been proven to be effective in improving the classification of
asthma and respiratory allergy, and therefore, in guiding targeted
therapies. Peters et al. described a gene expression network
analysis in sputum cells that can reveal airway immune-cell
dysfunction in asthma associated with three endotypes: T2-
low, T2-high, and T2-ultra high (32). Even so, the wealth of
information provided on asthma and respiratory allergy by this
type of complex studies is still underexploited (33, 34).
Further, this information must be contrasted and validated in
samples that are easy to process. Following this idea, this work
seeks to validate some of these results in PBMCs, specifically
of 94 genes described previously as possible biomarkers for
discrimination of asthma and respiratory allergy phenotypes
(21). Given the results of this genetic study, the most relevant
candidates were chosen to be assessed at the protein level.
The biomarkers found to be important at the genetic level for
distinguishing asthma and its severity were studied, and as the
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TABLE 3 | Receiver operating characteristic (ROC) curve analyses of the protein
expression combining two biomarkers.
CHI3L1 IL-10 IL-8 PI3 POSTN PHLDA1 SERPINB2
(A) TOTAL NA GROUP COMPARED TO TOTAL AA GROUP
CHI3L1 0.74 0.73 0.82 0.75 0.76 0.43 0.83
IL-10 – 0.45 0.71 0.46 0.87 ND ND
IL-8 – – 0.68 0.67 0.76 ND 0.82
PI3 – – – 0.57 0.67 0.6 0.69
POSTN – – – – 0.62 0.7 0.75
PHLDA1 – ND ND – – 0.4 0.80
SERPINB2 – ND – – – – 0.64
(B) SEVERE NA GROUP COMPARED TO SEVERE AA GROUP
CHI3L1 0.82 0.69 0.86 0.83 0.86 ND ND
IL-10 – 0.49 ND 0.68 0.94 ND ND
IL-8 – ND 0.63 0.69 0.86 ND ND
PI3 – – – 0.48 0.69 ND 0.92
POSTN – – – – 0.69 ND ND
PHLDA1 ND ND ND ND ND ND
SERPINB2 ND ND ND – ND ND 0.78
(C) MODERATE-MILD NA GROUP COMPARED TO MODERATE-MILD
AA GROUP
CHI3L1 0.66 0.60 0.80 0.63 0.72 ND 0.72
IL-10 – 0.60 ND 0.68 0.82 ND ND
IL-8 – ND 0.73 0.82 0.82 ND ND
PI3 – – – 0.62 0.67 ND 0.68
POSTN – – – – 0.53 ND 0.40
PHLDA1 ND ND ND ND ND ND ND
SERPINB2 – ND ND – – ND 0.60
(D) SEVERE AA GROUP COMPARED TO MODERATE-MILD AA GROUP
CHI3L1 0.50 0.47 0.82 0.58 0.50 ND 0.90
IL-10 – 0.46 ND 0.65 0.62 ND ND
IL-8 – ND 0.82 0.78 0.84 ND ND
PI3 – – – 0.56 0.54 ND 0.87
POSTN – – – – 0.52 ND 0.93
PHLDA1 ND ND ND ND ND ND ND
SERPINB2 – ND ND – – ND 0.77
Area under the curve values appearing in bold are >0.75 (good, very good, or excellent
results). ND: not determined due to a lack of data. Cells with a dash refer to a comparison
already shown in another cell of this table. Entries in gray indicate the individual ROC curve
analysis of the protein expression of the seven biomarkers. NA, nonallergic asthma; AA,
allergic asthma.
goal is to find easy-to-process biomarkers, simple techniques
such as ELISA or Western blot were used. Recently, we reported
on a group of genes and proteins that are differently expressed
in peripheral blood samples from patients with nonallergic
asthma (T2-low) compared to healthy control subjects, linking
some of these genes to disease severity (20). In this project,
the relevance of the gene and protein expression of potential
markers has been explored in depth by studying differences
in protein levels and through the analysis by ROC curves
using their individual and combined expression, with the goal
of demonstrating their capacity to discriminate between two
asthma phenotypes (nonallergic and allergic) and disease severity
using peripheral samples. These biomarkers were as follows:
TABLE 4 | Receiver operating characteristic (ROC) curve analysis of the protein
expression combining three biomarkers.
Combination of biomarkers NA vs. AA
AUC value
MM NA vs.
MM AA AUC
value
S NA vs. S
AA AUC
value
(A) NA GROUP COMPARED TO AA GROUP
CHI3L1 + IL-10 + IL-8 0.76 ND ND
CHI3L1 + IL-10 + PI3 0.71 0.68 0.72
CHI3L1 + IL-10 + POSTN 0.92 0.90 ND
CHI3L1 + IL-8 + PI3 0.82 0.71 0.88
CHI3L1 + IL-8 + POSTN 0.88 ND 0.96
CHI3L1 + PI3 + POSTN 0.80 0.80 0.86
CHI3L1 + PI3 + PHLDA1 0.63 ND ND
CHI3L1 + PI3 + SERPINB2 0.84 0.72 ND
CHI3L1 + POSTN + PHLDA1 0.77 ND ND
CHI3L1 + POSTN + SERPINB2 0.85 0.68 ND
CHI3L1 + PHLDA1 + SERPINB2 0.84 ND ND
IL-10 + IL-8+PI3 0.82 ND ND
IL-10 + IL-8+POSTN 0.87 ND ND
IL-10 + PI3 + POSTN 0.87 0.82 0.94
IL-8 + PI3 + POSTN 0.76 0.84 0.86
IL-8 + PI3 + SERPINB2 0.80 ND ND
IL-8 + POSTN+SERPINB2 0.82 ND ND
PI3 + POSTN + PHLDA1 0.67 ND ND
PI3 + POSTN + SERPINB2 0.77 0.64 ND
PI3 + PHLDA1+ SERPINB2 0.84 ND ND
Combination of biomarkers AUC value
(B) SEVERE AA GROUP COMPARED TO MODERATE-MILD AA GROUP
CHI3L1 + IL-10 + PI3 0.65
CHI3L1 + IL-10 + POSTN 0.63
CHI3L1 + IL-8 + PI3 0.82
CHI3L1 + IL-8 + POSTN 0.84
CHI3L1 + PI3 + POSTN 0.56
CHI3L1 + PI3 + SERPINB2 0.90
CHI3L1 + POSTN+ SERPINB2 0.93
IL-10 + PI3 + POSTN 0.74
IL-8 + PI3 + POSTN 0.82
PI3 + POSTN + SERPINB2 0.93
Numbers in bold denote area under the curve (AUC) values >0.75, which are considered
good (AUC: 0.76–0.90), very good (AUC: 0.91–0.97), or excellent (AUC: 0.98–1) results.
NA, nonallergic asthma; AA, allergic asthma; MM, group of subjects with moderate-mild
asthma; S, group of subjects with severe asthma.
CHI3L1, IL-8, IL-10, SERPINB2, PHLDA1, PI3, and POSTN.
The functional and pathological implications of these biomarkers
in asthma have been discussed previously (20, 21). Briefly,
CHI3L1 (chitinase 3-like 1) encodes a glycoprotein member
of the glycosyl hydrolase 18 family or YKL-40. This protein
has been extensively studied in relation with asthma, and
recently proposed not only as a potentially useful biomarker
for identification of severity, but also a potential therapeutic
target (35). IL-8 is a member of the CXC chemokine family
and one of the major mediators of the inflammatory response.
It is a chemo-attractant for neutrophils and very important for
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TABLE 5 | Ranking of the best individual and combined proteic biomarkers for
each discrimination.
AUC value (95% CI) Threshold
(A) BIOMARKERS ABLE TO DISCRIMINATE NA PATIENTS FROM
AA PATIENTS
CHI3L1 0.74 (0.61–0.88) 20,202
IL-10 + POSTN 0.87 (0.74–1.00) 457.4, 22,785
CHI3L1 + SERPINB2 0.83 (0.64–1.00) 20,202, 0.116
CHI3L1 + IL-8 0.82 (0.64–0.99) 20,202, 221
IL-8 + SERPINB2 0.82 (0.58–1.00) 221, 0.116
PHLDA1 + SERPINB2 0.80 (0.50–1.00) 0.012, 0.116
IL-8 + POSTN 0.76 (0.57–0.94) 221, 22,785
CHI3L1 + IL-10 + POSTN 0.92 (0.81–1.00) 20,202, 457.4, 22,785
CHI3L1 + IL-8 + POSTN 0.88 (0.76–1.00) 20,202, 221, 22,785
PI3 + PHLDA1 + SERPINB2 0.84 (0.57–1.00) 5,126, 0.012, 0.166
CHI3L1 + PI3 + POSTN 0.80 (0.68–0.91) 20,202, 5,126, 22,785
(B) BIOMARKERS ABLE TO DISCRIMINATE SEVERE NA PATIENTS FROM
SEVERE AA PATIENTS
CHI3L1 0.82 (0.67–0.98) 20,202
SERPINB2 0.78 (0.47–1.00) 0.11
IL-10 + POSTN 0.94 (0.83–1.00) 184.6, 22,785
PI3 + SERPINB2 0.92 (0.76–1.00) 5,758, 0.11
CHI3L1 + POSTN 0.86 (0.72–1.00) 20,202, 22,785
IL-8 + POSTN 0.86 (0.65–1.00) 122, 22,785
CHI3L1 + IL-8 0.86 (0.64–1.00) 20,202, 122
CHI3L1 + IL-8 + POSTN 0.96 (0.86–1.00) 20,202, 122, 22,785
(C) BIOMARKERS ABLE TO DISCRIMINATE MODERATE-MILD NA
PATIENTS FROM MODERATE-MILD AA PATIENTS
IL-10 + POSTN 0.82 (0.59–1.00) 167.9, 24,658
IL-8 + POSTN 0.82 (0.58–1.00) 221, 24,658
IL-8 + PI3 0.82 (0.53–1.00) 221, 5,028
CHI3L1 + IL-8 0.80 (0.51–1.00) 20,227, 221
CHI3L1 + IL-10 + POSTN 0.90 (0.72–1.00) 20,227, 167.9, 24,658
CHI3L1 + PI3 + POSTN 0.80 (0.64–0.97) 20,227, 5,028, 24,658
(D) BIOMARKERS ABLE TO DISCRIMINATE SEVERE AA PATIENTS FROM
MODERATE-MILD AA PATIENTS
IL-8 0.82 (0.58–1.00) 17
SERPINB2 0.77 (0.44–1.00) 0.095
POSTN + SERPINB2 0.93 (0.78–1.00) 19,119, 0.095
CHI3L1 + SERPINB2 0.90 (0.69–1.00) 24,144, 0.095
PI3 + SERPINB2 0.87 (0.59–1.00) 5,524, 0.095
IL-8 + POSTN 0.84 (0.62–1.00) 17, 19,119
Summary of the best options for discriminating each condition obtained from the ROC
curve analysis of protein expression from each of the seven biomarkers, either alone
or in combination. AUC value: area under the curve. 95% CI, 95% confidence interval.
Threshold means the protein levels of each biomarker able to discriminate each condition,
with the AUC indicated. Options with the best statistical power (95% CI between 0.70 and
1) appear in bold. NA, nonallergic asthma; AA, allergic asthma.
many neutrophil functions. This is one of the few biomarkers
proposed for asthma mediated by non type-2 inflammation.
In fact, the use of CXCR2 (the high-affinity receptor of IL8)
antagonist is one of the few targeted therapies proposed for
non type-2 inflammation, although until now no study could
demonstrate clinical effectiveness (36, 37). IL-10 is a cytokine
with pleiotropic effects, considered as one of the main regulatory
cytokines (38) and extensively associated with asthma and
allergy diseases (39). PHLDA1 (pleckstrin homology-like domain,
family A, member 1) has only been associated with asthma
diseases by our group (20, 21, 24). PI3 (peptidase inhibitor 3
skin-derived) encodes an elastase-specific inhibitor (elafin) that
inhibits serine proteases, such as human neutrophil elastase and
proteinase 3, to prevent excessive damage during inflammation.
It has been postulated as protective for asthma (40). Finally,
SERPINB2, a member of the serine protease inhibitor family,
was mainly associated with type 2 inflammation together with
POSTN (periostin) and CLCA1 in airway epithelial cells upon
IL13 stimulation (41).
Here, we propose the use of individual biomarkers and
where discrimination is not optimal, we argue in favor of
using sets of biomarkers for better patient characterization.
Therefore, the gene expression of CPA3 and IL-8 were found
to be important when differentiating between the two asthma
phenotypes as well as the severity of moderate-mild asthma
(Table 2). To discriminate patients with severe disease in the
two asthma groups, PI3 (AUC value: 0.78) was seen to be a
good biomarker (Table 2). Approaches using single parameters
are still important in the process of discovering biomarkers. Thus,
existing and newly identified biomarkers should be integrated to
reinforce the clinical value of stratifying asthmatic phenotypes
and endotypes (6).
At the protein level, both individually and in combination,
we have detected biomarkers with high potential (Tables 3, 4).
With strict criteria (best AUC value and 95% CI), the panels
of biomarkers that best differentiated our two groups and their
severity were as follows (Table 5): the combination of CHI3L1
+IL-10 +POSTN was very good for differentiating the NA from
the AA group, but also good for comparing moderate-mild
NA patients from moderate-mild AA subjects; CHI3L1 +IL-8
+ POSTN was very effective in discriminating severe asthma
within the NA group from the AA group [AUC value of 0.96
(0.86–1.00), Threshold: 20,202, 122, 22,785, Table 5]; and lastly,
the combination of POSTN and SERPINB2 is proposed as a
very useful test for comparing severe vs. moderate-mild AA
subjects. For patients with NA and different severities (severe vs.
moderate-mild), the combination of CHI3L1 + IL-8 + POSTN
has been previously proposed (20) as an excellent test [AUC value
of 0.98 (0.92–1.00), Threshold: 18,500, 841, 17,419]. The same
combination of biomarkers could be useful for discriminating
distinct groups of patients, given that threshold values and the
AUC are different in each case.
In summary, these results mark a starting point for the
improvement of asthma diagnosis and treatment. Though
encouraging, our results have several limitations that should be
addressed. Interesting would be to analyze the correlation of
expression between the peripheral sample levels and the target-
tissue of the disease. Indeed, the stability of these biomarkers
in time and their possible modification with medication should
be analyzed in longitudinal studies, in bigger populations, and
by different research groups to corroborate their validity and
reproducibility. Nowadays, overlap between different groups of
endotypes and the variety in the effects of therapy remains
substantial, and by further defining the pathogenesis of asthma
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we will be able to clarify these confusing differences. Our results
may help in this effort, given that we contribute new biomarkers
to the few that currently exist associated to the nonallergic
asthma and its severity. Moreover, we propose alternatives to the
biomarkers already used in clinical practice.
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